Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biomea Fusion Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BMEA
Nasdaq
8731
https://www.biomeafusion.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biomea Fusion Inc
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Apr 1st, 2024 8:10 pm
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
- Apr 1st, 2024 1:02 pm
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Apr 1st, 2024 1:00 pm
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
- Mar 7th, 2024 7:52 pm
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
- Mar 6th, 2024 8:04 am
Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
- Feb 19th, 2024 8:18 pm
3 Speculative Stocks That Could Make Your February Unforgettable
- Feb 18th, 2024 8:41 pm
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 9th, 2024 4:02 pm
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
- Jan 8th, 2024 2:00 pm
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 9:05 pm
We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
- Dec 20th, 2023 2:11 pm
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
- Dec 12th, 2023 2:27 pm
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
- Dec 11th, 2023 2:25 pm
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
- Dec 9th, 2023 10:30 pm
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
- Dec 8th, 2023 2:00 pm
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
- Dec 7th, 2023 2:15 pm
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
- Dec 5th, 2023 1:30 pm
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
- Nov 27th, 2023 1:30 pm
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
- Nov 16th, 2023 1:30 pm
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
- Nov 8th, 2023 9:05 pm
Scroll